Free Trial
Ends Tomorrow! Last Chance to Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim $100 Off
Claim MarketBeat All Access Sale Promotion
NASDAQ:IVVD

Invivyd Q4 2024 Earnings Report

Invivyd logo
$1.10 -0.01 (-0.90%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$1.13 +0.03 (+2.73%)
As of 05/22/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Invivyd EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Invivyd Revenue Results

Actual Revenue
$13.80 million
Expected Revenue
$13.57 million
Beat/Miss
Beat by +$233.00 thousand
YoY Revenue Growth
N/A

Invivyd Announcement Details

Quarter
Q4 2024
Date
3/20/2025
Time
Before Market Opens
Conference Call Date
Thursday, March 20, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Invivyd's Q4 2024 Press ReleasePress Release
(8-K)
Invivyd's Q4 2024 Annual reportAnnual report
(10-K)

Invivyd Earnings Headlines

Invivyd Shareholders Reelect Board, Ratify PwC Auditor
May 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/invivyd-shareholders-reelect-board-ratify-pwc-auditor?utm_source=marketbeat.com&utm_medium=referral
Invivyd's (IVVD) "Buy" Rating Reaffirmed at BTIG Research
May 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30786937
You cannot escape this reality
The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.tc pixel
May 24 at 1:00 AM  |  Porter & Company (Ad)
Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now
May 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/invivyd-ivvd-10-best-nasdaq-044932391.html
Wall Street Zen Downgrades Invivyd (NASDAQ:IVVD) to Strong Sell
May 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30780699
Invivyd outlines VYD2311 path as PEMGARDA grows 22% year-over-year while DECLARATION recruitment nears completion
May 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4593154-invivyd-outlines-vyd2311-path-as-pemgarda-grows-22-percent-year-over-year-while-declaration
See More Invivyd Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email.

About Invivyd

Invivyd (NASDAQ:IVVD), a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

View Invivyd Profile
Earnings Tools